Last reviewed 2026-04-23 · How we verify

AN2690

AN2690 is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNN4.

AN2690 is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNN4. Used for Treatment of focal epilepsy.

At a glance

Mechanism of action

By inhibiting KCNN4, AN2690 is thought to reduce the excitability of neurons and potentially alleviate symptoms associated with certain neurological disorders. However, the exact mechanism of action and therapeutic potential of AN2690 are still being investigated.

Approved indications

• Treatment of focal epilepsy

Common side effects

• Headache
• Dizziness
• Nausea

Key clinical trials

• Cumulative Irritation Test (PHASE1)
• Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail (PHASE3)
• Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail (PHASE3)
• Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I) (PHASE2)
• Study of Different Doses of a Novel Treatment for Onychomycosis (PHASE2)
• Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail (PHASE2)
• Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail (PHASE2)
• An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AN2690 CI brief — competitive landscape report
• AN2690 updates RSS · CI watch RSS
• Pfizer portfolio CI